Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Pawsey

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Menopause (New York, N.Y.)|February 19, 2020
Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trialMike Trower, Richard A Anderson, Elizabeth Ballantyne, et al.
Menopause (New York, N.Y.)|August 28, 2020
To the EditorSteve Pawsey, James A Simon, Richard A Anderson, et al.
The Journal of Clinical Endocrinology and Metabolism|February 24, 2021
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy WomenSteve Pawsey, Edouard Gregory Mills, Elizabeth Ballantyne, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 24, 2024
Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro BiotransformationSimone I Schulz, Marcus-Hillert Schultze-Mosgau, Anna Engelen, et al.
Menopause (New York, N.Y.)|January 31, 2023
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)James A Simon, Richard A Anderson, Elizabeth Ballantyne, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Menopause (New York, N.Y.)|February 19, 2020
Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trialMike Trower, Richard A Anderson, Elizabeth Ballantyne, et al.
Menopause (New York, N.Y.)|August 28, 2020
To the EditorSteve Pawsey, James A Simon, Richard A Anderson, et al.
The Journal of Clinical Endocrinology and Metabolism|February 24, 2021
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy WomenSteve Pawsey, Edouard Gregory Mills, Elizabeth Ballantyne, et al.
European Journal of Drug Metabolism and Pharmacokinetics|December 24, 2024
Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro BiotransformationSimone I Schulz, Marcus-Hillert Schultze-Mosgau, Anna Engelen, et al.
Menopause (New York, N.Y.)|January 31, 2023
Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)James A Simon, Richard A Anderson, Elizabeth Ballantyne, et al.
Pageof 1